Revance Therapeutics (RVNC) Tops Q4 EPS by 9c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Revance Therapeutics (RVNC) Tops Q4 EPS by 9c

Revance Reports Fourth Quarter and Full Year 2021 Financial Results, Provides Corporate Update

February 28, 2022 4:05 PM EST

- Announces the completion of three consecutive drug substance lots and one drug product lot as part of the qualification of new working cell bank, supporting BLA resubmission

- Fourth quarter and full year 2021 revenue for the RHA® Collection of dermal fillers of $23.8 million, and $70.8 million, respectively, with over 3,000 aesthetic accounts across products and services

- Cash, cash equivalents and short-term investments of $225.1 million

- Conference call and webcast today at 4:30 p.m. ET.

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company... More